Effects of antihypertensive treatment on small artery remodelling

Enrico Agabiti-Rosei1, Anthony M Heagerty, Damiano Rizzoni

  • 1Clinica Medica, Department of Medical and Surgical Sciences, University of Brescia, Italy.

Insights

Hypertension causes structural changes in blood vessels. Small artery alterations, distinct from hypertrophy, may predict patient outcomes, necessitating research into reversing these changes.

Area of Science:

  • Cardiovascular Medicine
  • Vascular Biology
  • Hypertension Research

Background:

  • Hypertension leads to structural changes in systemic vasculature.
  • Medium and large vessels show medial smooth muscle hypertrophy, similar to the left ventricle.
  • Small arteries, crucial for vascular resistance, exhibit distinct changes in hypertension.

Purpose of the Study:

  • To investigate the structural alterations in small arteries in different forms of hypertension.
  • To explore the prognostic significance of vascular architectural changes.
  • To review the potential of antihypertensive therapies in reversing vascular structural changes.

Main Methods:

  • Histological examination of vascular tissue from hypertensive patients and animal models.
  • Analysis of vascular wall structure, lumen size, and cell morphology in small arteries.
  • Review of existing literature on antihypertensive drug effects on vascular remodeling.

Main Results:

  • Essential hypertension involves small vessel smooth muscle cell restructuring around a smaller lumen, without hypertrophy.
  • Secondary hypertension and non-insulin-dependent diabetes mellitus show hypertrophic remodeling.
  • Vascular architectural alterations in small arteries may hold significant prognostic value beyond traditional risk factors.

Conclusions:

  • Structural changes in small arteries differ between hypertension types and comorbidities.
  • These architectural alterations may be critical prognostic indicators in hypertensive patients.
  • Further research is urgently needed on the prognostic impact of regressing vascular structural changes and the role of antihypertensive therapy.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...